Please login to the form below

Not currently logged in
Email:
Password:

JAK inhibitor

This page shows the latest JAK inhibitor news and features for those working in and with pharma, biotech and healthcare.

Eli Lilly and Incyte's Olumiant approved by FDA for hospitalised COVID-19 patients

Eli Lilly and Incyte's Olumiant approved by FDA for hospitalised COVID-19 patients

This is the first and only FDA-approved Janus kinase (JAK) inhibitor for the treatment of hospitalised COVID-19 patients.

Latest news

More from news
Approximately 6 fully matching, plus 85 partially matching documents found.

Latest Intelligence

  • 20 for 2020 – Five pharma leaders to watch in 2020 20 for 2020 – Five pharma leaders to watch in 2020

    The decade-long $5.1bn alliance, announced in July, came on the heels of a long relationship between the two companies that had already yielded a late-stage candidate, JAK inhibitor ... and filgotinib’s anticipated launch this year meets expectations

  • 20 for 2020 – Five pharma companies to watch 20 for 2020 – Five pharma companies to watch

    AbbVie needs its new products to deliver quickly, and that includes recently approved JAK inhibitor Rinvoq (upadacitinib) for arthritis and psoriasis therapy Skyrizi (risankizumab) – both tipped as possible future blockbusters despite ... checkpoint

  • Drug launches to watch in 2019 Drug launches to watch in 2019

    These include Pfizer’s Daurismo, the first smoothened (SMO) receptor inhibitor to be approved for blood cancer. ... t the only oral JAK inhibitor developer with its eye on that particular prize.

  • Deal Watch January 2018

    Royalty monetisation. 230. Jiangsu Hengrui Medicine/Arcutis. SHR0302, selective JAK inhibitor, for dermatology disorders (currently p2 for RA in China). ... This acquisition brings tucatinib, an oral tyrosine kinase inhibitor that is highly selective for

  • Deal Watch table for December 2014 Deal Watch table for December 2014

    Company acquisition. 3, 500. Astellas/ J&J. ASP015K, an oral JAK inhibitor for RA (p3). ... ONT-380 (ARRY-380), oral, reversible and selective small molecule HER2 inhibitor (p1).

More from intelligence
Approximately 0 fully matching, plus 7 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 1 fully matching, plus 1 partially matching documents found.

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
ahair@onyxhealth.com

Onyx Health is a healthcare communications and PR agency based in the North East of England, but with a national...

Latest intelligence

Our Top 5 Pharma Picks From Cannes Lions
Here are five of Art's top five pharma and healthcare picks from Cannes Lions 2022....
The Evolving Role of the Sales Rep
The COVID-19 pandemic sparked an evolution in physician engagement. Jill Padgett, EdD, Head of Training, explores what this means for the sales force and shares her advice for succeeding in...
Measure your omnichannel maturity with our new tool
Try our Omnichannel Maturity Tool to gain tangible advice and an instant analysis of your omnichannel readiness....